Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | TEK | Q02763 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194979 | 0.95 | EGFR (0.46) | EGFRERBB2KDR | |
| SCHEMBL2198361 | 0.94 | EGFR (0.49) | EGFRERBB2 | |
| SCHEMBL2194993 | 0.94 | EGFR (0.49) | EGFRERBB2 | |
| SCHEMBL2194943 | 0.93 | EGFR (0.50) | EGFRERBB2 | |
| SCHEMBL2194885 | 0.93 | EGFR (0.52) | EGFRERBB2AURKA | |
| SCHEMBL2194859 | 0.93 | EGFR (0.59) | EGFRERBB2 | |
| SCHEMBL2193775 | 0.93 | EGFR (0.46) | EGFRERBB2AURKAPDGFRBTEK | |
| SCHEMBL2196578 | 0.92 | EGFR (0.48) | EGFRERBB2 | |
| SCHEMBL2195622 | 0.91 | ERBB2 (0.58) | EGFRERBB2 | |
| SCHEMBL2194192 | 0.91 | EGFR (0.48) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | EGFR 2146/4885ERBB2 1762/4885AURKA 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.